Breast-specific gamma imaging (BSGI) developer Dilon Diagnostics is directing attention to a recent multicenter patient registry that found that its BSGI technology improves breast cancer detection when added to mammography and ultrasound in the breast clinic.
In the study, presented at the National Consortium of Breast Centers (NCBC) annual meeting earlier this month, BSGI detected cancers in nearly 13% of patients with negative or indeterminate mammograms and an unresolved diagnostic concern. BSGI detected a high-risk lesion in 4% of these patients, according to Dilon.
Furthermore, BSGI detected 92% of cancers, outperforming ultrasound's 60% cancer detection rate, Dilon said.
Study co-author Dr. Jean Weigert of Mandell and Blau MDs in New Britain, CT, said that the results demonstrate that BSGI can detect some cancers in cases where mammography and ultrasound are negative or indeterminate.
